Novan (NOVN) could be a great long-term investment
What’s up with Novan?
Novan (NOVN) opened at $0.33, which means the stock is down 3.40% from yesterday’s closing price of 0.35. Today, the company has a high of $3.72 and a low of $0.22. The company has a market cap of $23.10 million with a 52-week high of $3.72 and a 52-week low of $0.22.
What about the future for Novan?
The high forecast for Novan is 1.50 while the low is 0.50. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. Novan has a strong forecast. A strong forecast is a result of strong earning reports as investors are willing to pay a higher share price today because of growth expectations in the future. Based on this information NOVN seems to be a safe buy.
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. Its products pipeline include SB204, SB206, SB208, and SB414. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Morrisville, NC.